Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
The primary objective of this study is to evaluate the antiviral efficacy, safety, and
 tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC)
 and ribavirin (RBV) in participants with chronic genotype 1 or 2 hepatitis C virus (HCV)
 infection who have previously failed a direct-acting antiviral (DAA)-containing regimen.
Key Inclusion Criteria:

 -  Genotype 1 or 2 HCV infection

 -  Chronic HCV infection (≥ 6 months prior to screening) documented by prior medical
 history or liver biopsy

 -  Previously treated with a DAA-containing regimen of at least 4 week duration

 Note: Other protocol defined Inclusion/Exclusion criteria may apply.